Literature DB >> 18430775

Cardiac status after childhood growth hormone treatment of Turner syndrome.

Jochem van den Berg1, Ellen M N Bannink, Piotr A Wielopolski, Wim C J Hop, Lennie van Osch-Gevers, Peter M T Pattynama, Sabine M P F de Muinck Keizer-Schrama, Willem A Helbing.   

Abstract

CONTEXT: In Turner syndrome (TS), GH treatment is well established. Data on cardiac status after discontinuation of treatment are scarce. This study aimed to assess biventricular size and function in TS at least 6 months after discontinuation of GH treatment.
METHODS: TS patients and healthy women prospectively underwent cardiac magnetic resonance imaging. Ventricular two-dimensional tomographic cine data were acquired to obtain biventricular volume, mass, and ejection fraction. Atrioventricular valve flow measurements were performed using a two-dimensional flow-sensitized sequence. Flow velocity curves were calculated and indices of biventricular diastolic filling were derived.
RESULTS: Thirty-one patients [mean (sd) age 20 (2) yr, body surface area 1.75 (0.15) m(2), 5 (2) yr after GH discontinuation] and 23 normal control women [age 21 (2) yr, body surface area 1.80 (0.13) m(2)] were included. Compared with controls, patients had smaller mean end-diastolic volumes [right ventricle (RV), 84 (11) ml/m(2) vs. 79 (10), P = 0.02; left ventricle (LV), 81 (10) vs. 72 (9), P < 0.001], end-systolic volumes [RV 38 (7) ml/m(2) vs. 36 (6), P = 0.04; LV 34 (5) vs. 29 (4), P < 0.001], and stroke volumes [RV 46 (6) ml/m(2) vs. 43 (6), P = 0.03; LV, 47 (7) vs. 44 (4), P = 0.02]. Patients had a higher mean heart rate [79 (13) beats/min vs. 71 (10), P < 0.05]. Biventricular ejection fraction, mass, cardiac output, and diastolic filling pattern were comparable.
CONCLUSION: After discontinuation of GH treatment TS patients showed no myocardial hypertrophy and well-preserved biventricular function. Ventricular volumes were smaller in Turner patients, compared with controls, whereas mean heart rate was higher. These last observations may be part of the natural development in TS and not linked to GH treatment, which at this point we consider safe.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430775     DOI: 10.1210/jc.2007-2313

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart Disease.

Authors:  A Uçar; Melike Tuğrul; Bülent Oğuz Erol; Ensar Yekeler; Banu Aydın; Seher Yıldız; Kemal Nişli; Firdevs Baş; Şükran Poyrazoğlu; Feyza Darendeliler; Nurçin Saka; Aylin Yetim Şahin; Yasin Yılmaz; Rüveyde Bundak
Journal:  Pediatr Cardiol       Date:  2018-02-01       Impact factor: 1.655

2.  Turner syndrome in childhood and adolescence.

Authors:  Kateri McCarthy; Carolyn A Bondy
Journal:  Expert Rev Endocrinol Metab       Date:  2008

3.  Cardiovascular pathology in males and females with 45,X/46,XY mosaicism.

Authors:  Katya De Groote; Martine Cools; Jean De Schepper; Margarita Craen; Inge François; Daniel Devos; Karlien Carbonez; Benedicte Eyskens; Daniel De Wolf
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

4.  The Usefulness of Magnetic Resonance Imaging of the Cardiovascular System in the Diagnostic Work-Up of Patients With Turner Syndrome.

Authors:  Monika Obara-Moszynska; Justyna Rajewska-Tabor; Szymon Rozmiarek; Katarzyna Karmelita-Katulska; Anna Kociemba; Barbara Rabska-Pietrzak; Magdalena Janus; Andrzej Siniawski; Bartlomiej Mrozinski; Agnieszka Graczyk-Szuster; Marek Niedziela; Malgorzata Pyda
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-16       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.